Cytokinetics (CYTK) Misses Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $57.40 -9.75%
Financial Fact:
Operating loss: 32.49M
Today's EPS Names:
KELYA, ROX, KEEL, More
Financial Fact:
Operating loss: 32.49M
Today's EPS Names:
KELYA, ROX, KEEL, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($1.36), $0.13 worse than the analyst estimate of ($1.23). Revenue for the quarter came in at $463 thousand versus the consensus estimate of $1.21 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MercadoLibre shares fall on earnings miss, margin pressure
- Ralph Lauren (RL) Tops Q2 EPS by 41c
- SanDisk shares drop amid chip sector selloff
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
